Chemoinformaics analysis of 5-(Beta-D-Xylopyranoside)-L-Arabinose
| Molecular Weight | 282.245 | nRot | 3 |
| Heavy Atom Molecular Weight | 264.101 | nRig | 11 |
| Exact Molecular Weight | 282.095 | nRing | 2 |
| Solubility: LogS | -0.018 | nHRing | 2 |
| Solubility: LogP | -2.884 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 37 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 19 | No. of Aromatic Carbocycles | 0 |
| nHetero | 9 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 18 | No. of Saturated Hetero Cycles | 2 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 9 | No. of Arom Bond | 0 |
| nHA | 9 | APOL | 35.9203 |
| nHD | 6 | BPOL | 23.2657 |
| QED | 0.303 |
| Synth | 4.254 |
| Natural Product Likeliness | 2.57 |
| NR-PPAR-gamma | 0.007 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.002 |
| Pgp-sub | 0.811 |
| HIA | 0.965 |
| CACO-2 | -5.702 |
| MDCK | 0.000344574 |
| BBB | 0.475 |
| PPB | 0.126606 |
| VDSS | 0.321 |
| FU | 0.732309 |
| CYP1A2-inh | 0.002 |
| CYP1A2-sub | 0.033 |
| CYP2c19-inh | 0.01 |
| CYP2c19-sub | 0.069 |
| CYP2c9-inh | 0 |
| CYP2c9-sub | 0.136 |
| CYP2d6-inh | 0.003 |
| CYP2d6-sub | 0.12 |
| CYP3a4-inh | 0.004 |
| CYP3a4-sub | 0.004 |
| CL | 1.214 |
| T12 | 0.589 |
| hERG | 0.051 |
| Ames | 0.309 |
| ROA | 0.228 |
| SkinSen | 0.027 |
| Carcinogencity | 0.02 |
| EI | 0.017 |
| Respiratory | 0.023 |
| NR-Aromatase | 0.007 |
| Antiviral | No |
| Prediction | 0.764974 |